What is claimed is:

1. A compound comprising a modified oligonucleotide consisting of 16 to 22 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 16 contiguous nucleosides of the following nucleoside pattern I in the 5' to 3' orientation:

   $(R)_X$-N^B-N^Q-N^Q-N^B-$(N^Q$-N^Q-N^Q-$N^B)_3$-N^Q-N^Z

   wherein each R is, independently, a non-bicyclic nucleoside; X is from 1 to 4;

   each N^B is, independently, a bicyclic nucleoside;

   each N^Q is, independently, a non-bicyclic nucleoside; and

   each N^Z is, independently, a modified nucleoside, and wherein

   (i) each bicyclic nucleoside comprises a non-methylated nucleobase, or

   (ii) no more than two non-bicyclic nucleosides are 2'-O-methoxyethyl nucleosides and each other non-bicyclic nucleoside is a β-D-deoxyribonucleoside.

2. A compound comprising a modified oligonucleotide consisting of 16 to 19 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 16 contiguous nucleosides of the following nucleoside pattern II in the 5' to 3' orientation:

   N^M-N^B-N^Q-N^Q-N^B-$(N^Q$-N^Q-N^Q-$N^B)_3$-N^Q-N^Z

   wherein N^M is, independently, a modified nucleoside that is not a bicyclic nucleoside;

   each N^B is, independently, a bicyclic nucleoside;

   each N^Q is, independently, a non-bicyclic nucleoside; and

   N^Z is, independently, a modified nucleoside, and wherein

   (i) each bicyclic nucleoside comprises a non-methylated nucleobase, or

   (ii) no more than two non-bicyclic nucleosides are 2'-O-methoxyethyl nucleosides and each other non-bicyclic nucleoside is a β-D-deoxyribonucleoside.

3. A compound comprising a modified oligonucleotide consisting of 16 to 19 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 16 contiguous nucleosides of the following nucleoside pattern III in the 5' to 3' orientation:

   $(R)_X$-N^B-N^Q-N^Q-N^B-$(N^Q$-N^Q-N^Q-$N^B)_3$-N^Y-N^Z

wherein each R is a non-bicyclic nucleoside; X is from 1 to 4;

each N^B is a bicyclic nucleoside;

each N^Q is a non-bicyclic nucleoside;

N^Y is a modified nucleoside or an unmodified nucleoside; and

each N^Z is a modified nucleoside, and wherein

(i) each bicyclic nucleoside comprises a non-methylated nucleobase, or

(ii) no more than two non-bicyclic nucleosides are 2'-O-methoxyethyl nucleosides and each other non-bicyclic nucleoside is a β-D-deoxyribonucleoside.

4. A compound comprising a modified oligonucleotide consisting of 16 to 19 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 16 contiguous nucleosides of the following nucleoside pattern IV in the 5' to 3' orientation:

N^M-N^B-N^Q-N^Q-N^B-(N^Q-N^Q-N^Q-N^B)$_3$-N^Y-N^Z

wherein N^M is a modified nucleoside that is not a bicyclic nucleoside;

each N^B is a bicyclic nucleoside;

each N^Q is a non-bicyclic nucleoside;

N^Y is a modified nucleoside or an unmodified nucleoside; and

N^Z is a modified nucleoside, and wherein

(i) each bicyclic nucleoside comprises a non-methylated nucleobase, or

(ii) no more than two non-bicyclic nucleosides are 2'-O-methoxyethyl nucleosides and each other non-bicyclic nucleoside is a β-D-deoxyribonucleoside.

5. A compound comprising a modified oligonucleotide consisting of 16 to 19 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 16 contiguous nucleosides of the following nucleoside pattern V in the 5' to 3' orientation:

N^M-N^B-(N^Q-N^Q-N^B-N^B)$_4$-N^Z

wherein N^M is a modified nucleoside that is not a bicyclic nucleoside;

each N^B is a bicyclic nucleoside;

each N^Q is a non-bicyclic nucleoside; and

N^Z is a modified nucleoside.

6. The compound of any one of claims 1 to 5, wherein the modified oligonucleotide comprises at least 17, at least 18, at least 19, at least 20, at least 21, or 22 contiguous nucleosides of nucleoside pattern I, II, III, IV or V.
7. The compound of any one of the preceding claims, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary is at least 95% complementary, or is 100% complementary to the nucleobase sequence of miR-21 (SEQ ID NO: 1).
8. The compound of any one of the preceding claims wherein each bicyclic nucleoside is independently selected from an LNA nucleoside, a cEt nucleoside, and an ENA nucleoside.
9. The compound of any one of claims 1 to 7, wherein each bicyclic nucleoside is an S-cEt nucleoside.
10. The compound of any one of claims 1 to 7, wherein each bicyclic nucleoside is an LNA nucleoside.
11. The compound of any one of the preceding claims wherein each non-bicyclic nucleoside is independently selected from a β-D-deoxyribonucleoside and a 2'-O-methoxyethyl nucleoside.
12. The compound of any one of claims 1 to 10 wherein each non-bicyclic nucleoside is a β-D-deoxyribonucleoside.
13. The compound of any one of claims 1 to 10 wherein each non-bicyclic nucleoside is a 2'-O-methoxyethyl nucleoside.
14. The compound of any one of the preceding claims wherein the modified oligonucleotide consists of 16, 17, 18, 19, 20, 21, or 22 linked nucleosides of nucleoside pattern I, II, III, IV or V.

15. The compound of any one of claims 1 to 14 wherein at least one cytosine is a 5-methyl cytosine, or wherein each cytosine is a 5-methylcytosine.
16. The compound of claim 1 wherein:

a. R consists of four linked nucleosides N^{R1}-N^{R2}-N^{R3}-N^{R4}, wherein N^{R1} is a 2'-O-methoxyethyl nucleoside and each of N^{R2}-N^{R3}-N^{R4} is a β-D-deoxyribonucleoside;
each N^{B} is an S-cEt nucleoside;
each N^{Q} is a β-D-deoxyribonucleoside; and
N^{Z} is a 2'-O-methoxyethyl nucleoside;

b. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside;

c. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an S-cEt nucleoside;

each N^Q is a 2'-O-methoxyethyl nucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside;

d. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is an S-cEt nucleoside;

e. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an LNA nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside; or

f. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an LNA nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is an LNA nucleoside.

17. The compound of claim 1, wherein the modified oligonucleotide has a structure selected from:

$T_E{}^{Me}C_EA_EA_EC_SA_ET_EC_SA_EG_ET_EC_ST_EG_EA_EU_SA_EA_EG_EC_ST_EA_E$, and

$T_E{}^{Me}CAAC_SATC_SAGTC_STGAU_SAAGC_STA_E$

wherein nucleosides not followed by a subscript are β-D-deoxyribonucleosides, nucleosides followed by a subscript "E" are 2'-MOE nucleosides, nucleosides followed by a subscript "S" are S-cEt nucleosides, and superscript "Me" indicates a 5-methyl group on the base of the nucleoside.

18. The compound of claim 2 wherein:

a. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside;

b. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an S-cEt nucleoside;

each N^Q is a 2'-O-methoxyethyl nucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside;

c. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside;

each N is a β-D-deoxyribonucleoside; and

N^Z is an S-cEt nucleoside;

d. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an LNA nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside; or

e. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an LNA nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is an LNA nucleoside.

19. The compound of claim 2, wherein the modified oligonucleotide has a structure selected from:

$A_EC_SATC_SAGTC_STGAU_SAAGC_STA_E$,

$A_EC_SA_ET_EC_SA_EG_ET_EC_ST_EG_EA_EU_SA_EA_EG_EC_ST_EA_E$,

$A_E^{Me}C_SAT^{Me}C_SAGT^{Me}C_STGAT_SAAG^{Me}C_STA_E$,

$A_EC_SATC_SAGTC_STGAU_SAAGC_STA_S$, and

$A_E^{Me}C_SAT^{Me}C_SAGT^{Me}C_STGAT_SAAG^{Me}C_STA_S$,

wherein nucleosides not followed by a subscript are β-D-deoxyribonucleosides, nucleosides followed by a subscript "E" are 2'-MOE nucleosides, nucleosides followed by a subscript "S" are S-cEt nucleosides, and superscript "Me" indicates a 5-methyl group on the base of the nucleoside.

20. The compound of claim 19, wherein the modified oligonucleotide has the structure:

$A_EC_SATC_SAGTC_STGAU_SAAGC_STA_E$,

wherein nucleosides not followed by a subscript are β-D-deoxyribonucleosides, nucleosides followed by a subscript "E" are 2'-MOE nucleosides, and nucleosides followed by a subscript "S" are S-cEt nucleosides.

21. The compound of claim 3 wherein:

a. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside;

N^Y is a β-D-deoxyribonucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside;

b. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside;

N^Y is a β-D-deoxyribonucleoside; and

N^Z is an S-cEt nucleoside; or

c. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside;

N^Y is an S-cEt nucleoside; and

N^Z is an S-cEt nucleoside.

22. The compound of claim 4 wherein:

a. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside;

N^Y is a β-D-deoxyribonucleoside;

N^Z is a 2'-O-methoxyethyl nucleoside; and

b. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside;

N^Y is a β-D-deoxyribonucleoside; and

N^Z is an S-cEt nucleoside;

c. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside;

N^Y is an S-cEt nucleoside; and

N^Z is an S-cEt nucleoside.

23. The compound of claim 5 wherein:

N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside.

24. The compound of any one of the preceding claims wherein the modified oligonucleotide has the nucleobase sequence of SEQ ID NO: 3 or wherein the modified oligonucleotide has the nucleobase sequence of SEQ ID NO: 4, and wherein each T in the sequence is independently selected from a T and a U.
25. The compound of any one of the preceding claims, wherein at least one internucleoside linkage is a modified internucleoside linkage, or wherein each internucleoside linkage is a modified internucleoside linkage, and wherein the modified internucleoside linkage is optionally a phosphorothioate internucleoside linkage.
26. A modified oligonucleotide having the structure:
$A_ECsATCsAGTCsTGAUsAAGCsTA_E$,
wherein nucleosides not followed by a subscript are β-D-deoxyribonucleosides, nucleosides followed by a subscript "E" are 2'-MOE nucleosides, and nucleosides followed by a subscript "S" are S-cEt nucleosides; and wherein each internucleoside linkage is a phosphorothioate linkage.
27. A pharmaceutical composition comprising the modified oligonucleotide of claim 26 and a pharmaceutically acceptable carrier.
28. Use of a compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26 in the manufacture of a medicament for inhibiting the activity of miR-21 in a cell, wherein the medicament is to be contacted to a cell.
29. The use of claim 28, wherein the cell is *in vivo* or wherein the cell is *in vitro*.
30. The use of claim 28 or 29 wherein the cell is a fibroblast cell, a hyperproliferative cell, a keratinocyte, or a hypoxic cell.
31. Use of a compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26 in the manufacture of a medicament for decreasing collagen expression in a cell, wherein the medicament is to be contacted to a cell.
32. Use of a compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26 in the manufacture of a medicament for treating, preventing or delaying the onset of a disease associated with miR-21 in a subject having a disease associated with miR-21, wherein the medicament is to be adiministered into the subject having a disease associated with miR-21.
33. The use of claim 32, wherein the disease is fibrosis.
34. The use of claim 33, wherein the fibrosis is selected from kidney fibrosis, lung fibrosis, liver fibrosis, cardiac fibrosis, skin fibrosis, age-related fibrosis, spleen fibrosis, scleroderma, and post-transplant fibrosis.

35. The use of claim 34 wherein:
    a. the kidney fibrosis is present in a subject having a disease selected from glomerulosclerosis, tubulointerstitial fibrosis, IgA nephropathy, interstitial fibrosis/tubular atrophy; chronic kidney damage, glomerular disease, glomerulonephritis, diabetes mellitus, idiopathy focal segmental glomerulosclerosis, membranous nephropathy, collapsing glomerulopathy, chronic recurrent kidney infection, and end stage renal disease;
    b. the kidney fibrosis results from acute or repetitive trauma to the kidney;
    c. the liver fibrosis is present in a subject having a disease selected from chronic liver injury, hepatitis infection, non-alcoholic steatohepatitis, and cirrhosis; the pulmonary fibrosis is idiopathic pulmonary fibrosis; and/or
    d. the subject has chronic obstructive pulmonary disease.
36. Use of a compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26 in the manufacture of a medicament for treating a fibroproliferative disorder in a subject, wherein the medicament is to be administered into the subject.
37. The use of any one of claims 32 to 36 comprising selecting a subject having elevated miR-21 expression in one or more tissues.
38. The use of any one of claims 32 to 36 wherein the subject is in need of improved organ function, wherein the organ function is selected from cardiac function, pulmonary function, liver function, and kidney function.
39. The use of any one of claims 32 to 38 wherein the adminstration improves organ function in the subject, wherein the organ function is selected from cardiac function, pulmonary function, liver function, and kidney function.
40. The use of any one of claims 32 to 39 wherein said treatment comprising administration of at least one therapeutic agent selected from an anti-inflammatory agent, an immunosuppressive agent, an anti-diabetic agent, digoxin, a vasodilator, an angiotensin II converting enzyme (ACE) inhibitors, an angiotensin II receptor blockers (ARB), a calcium channel blocker, an isosorbide dinitrate, a hydralazine, a nitrate, a hydralazine, a beta-blocker, a natriuretic peptides, a heparinoid, and a connective tissue growth factor inhibitor.
41. The use of claim 40, wherein said therapeutic agent is at least one ACE inhibitor.
42. The use of claim 41, wherein the ACE inhibitor is selected from captopril, enalapril, lisinopril, benazepril, quinapril, fosinopril, and ramipril.
43. The use of claim 40, comprising administration of at least one ARB inhibitor.

44. The use of claim 43, wherein the ARB inhibitor is selected from candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, and eprosartan.
45. The use of claim 32, wherein the disease is cancer.
46. The use of claim 45 wherein the cancer is liver cancer, breast cancer, bladder cancer, prostate cancer, colon cancer, lung cancer, brain cancer, hematological cancer, pancreatic cancer, head and neck cancer, cancer of the tongue, stomach cancer, skin cancer, or thyroid cancer.
47. The use of any one of claims 45 or 46 wherein said treatment further comprising administration of at least one additional anti-cancer therapy to the subject.
48. The use of any one of claims 32 to 47, wherein the subject is a human.
49. The use of any one of claims 32 to 48, wherein the compound is present as a pharmaceutical composition.
50. A compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26, for use in therapy.
51. A compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26, for use in the treatment of fibrosis.
52. A compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26, for use in promoting wound healing.
53. A compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26, for use in treating cancer.
54. A compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26, for use in preventing and/or delaying the onset of metastasis.
55. A compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26, for use in treating cardiac disease.
56. Use of a compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26 for the preparation of a medicament.
57. Use of a compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26 for the preparation of a medicament for treating fibrosis.
58. Use of a compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26 for the preparation of a medicament for promoting wound healing.
59. Use of a compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26 for the preparation of a medicament for treating cancer.

60. Use of a compound of any one of claims 1 to 25 or the modified oligonucleotide of claim 26 for the preparation of a medicament for preventing and/or delaying the onset of metastasis.

What is claimed is:

1. A compound comprising a modified oligonucleotide consisting of 8 to 22 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following nucleoside pattern I in the 5' to 3' orientation:

   $(R)_X$-N^B-N^Q-N^Q-N^B-$(N^Q$-N^Q-N^Q-$N^B)_3$-N^Q-N^Z

   wherein each R is, independently, a non-bicyclic nucleoside; X is from 1 to 4;

   each N^B is, independently, a bicyclic nucleoside;

   each N^Q is, independently, a non-bicyclic nucleoside; and

   each N^Z is, independently, a modified nucleoside.

2. A compound comprising a modified oligonucleotide consisting of 8 to 19 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following nucleoside pattern II in the 5' to 3' orientation:

   N^M-N^B-N^Q-N^Q-N^B-$(N^Q$-N^Q-N^Q-$N^B)_3$-N^Q-N^Z

   wherein N^M is, independently, a modified nucleoside that is not a bicyclic nucleoside;

   each N^B is, independently, a bicyclic nucleoside;

   each N^Q is, independently, a non-bicyclic nucleoside; and

   N^Z is, independently, a modified nucleoside.

3. A compound comprising a modified oligonucleotide consisting of 8 to 19 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following nucleoside pattern III in the 5' to 3' orientation:

   $(R)_X$-N^B-N^Q-N^Q-N^B-$(N^Q$-N^Q-N^Q-$N^B)_3$-N^Y-N^Z

   wherein each R is a non-bicyclic nucleoside; X is from 1 to 4;

   each N^B is a bicyclic nucleoside;

   each N^Q is a non-bicyclic nucleoside;

   N^Y is a modified nucleoside or an unmodified nucleoside; and

   each N^Z is a modified nucleoside.

4. A compound comprising a modified oligonucleotide consisting of 8 to 19 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following nucleoside pattern IV in the 5' to 3' orientation:

N^M-N^B-N^Q-N^Q-N^B-(N^Q-N^Q-N^Q-N^B)$_3$-N^Y-N^Z

wherein N^M is a modified nucleoside that is not a bicyclic nucleoside;

each N^B is a bicyclic nucleoside;

each N^Q is a non-bicyclic nucleoside;

N^Y is a modified nucleoside or an unmodified nucleoside; and

N^Z is a modified nucleoside.

5. A compound comprising a modified oligonucleotide consisting of 8 to 19 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following nucleoside pattern V in the 5' to 3' orientation:

N^M-N^B-(N^Q-N^Q-N^B-N^B)$_4$-N^Z

wherein N^M is a modified nucleoside that is not a bicyclic nucleoside;

each N^B is a bicyclic nucleoside;

each N^Q is a non-bicyclic nucleoside; and

N^Z is a modified nucleoside.

6. The compound of any of claims 1 to 5, wherein the modified oligonucleotide comprises at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or 22 contiguous nucleosides of nucleoside pattern I, II, III, IV or V.
7. The compound of any of the above claims, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary is at least 95% complementary, or is 100% complementary to the nucleobase sequence of miR-21 (SEQ ID NO: 1).
8. The compound of any of the above claims wherein each bicyclic nucleoside is independently selected from an LNA nucleoside, a cEt nucleoside, and an ENA nucleoside.
9. The compound of any of claims 1 to 7, wherein each bicyclic nucleoside is an S-cEt nucleoside.

10. The compound of any of claims 1 to 7, wherein each bicyclic nucleoside is an LNA nucleoside.
11. The compound of any of the above claims wherein each non-bicyclic nucleoside is independently selected from a β-D-deoxyribonucleoside and a 2'-O-methoxyethyl nucleoside.
12. The compound of any of claims 1 to 10 wherein each non-bicyclic nucleoside is a β-D-deoxyribonucleoside.
13. The compound of any of claims 1 to 10 wherein each non-bicyclic nucleoside is a 2'-O-methoxyethyl nucleoside.
14. The compound of any of the above claims wherein the modified oligonucleotide consists of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 linked nucleosides of nucleoside pattern I, II, III, IV or V.
15. The compound of any of the above claims wherein at least one internucleoside linkage is a modified internucleoside linkage, or wherein each internucleoside linkage is a modified internucleoside linkage, and wherein the modified internucleoside linkage is optionally a phosphorothioate internucleoside linkage.
16. The compound of any of claims 1 to 15 wherein at least one cytosine is a 5-methyl cytosine, or wherein each cytosine is a 5-methylcytosine.
17. The compound of claim 1 wherein:

a. R consists of four linked nucleosides N^{R1}-N^{R2}-N^{R3}-N^{R4}, wherein N^{R1} is a 2'-O-methoxyethyl nucleoside and each of N^{R2}-N^{R3}-N^{R4} is a β-D-deoxyribonucleoside;
each N^{B} is an S-cEt nucleoside;
each N^{Q} is a β-D-deoxyribonucleoside; and
N^{Z} is a 2'-O-methoxyethyl nucleoside;

b. each R is a 2'-O-methoxyethyl nucleoside; X is 1;
each N^{B} is an S-cEt nucleoside;
each N^{Q} is a β-D-deoxyribonucleoside; and
N^{Z} is a 2'-O-methoxyethyl nucleoside;

c. each R is a 2'-O-methoxyethyl nucleoside; X is 1;
each N^{B} is an S-cEt nucleoside;
each N^{Q} is a 2'-O-methoxyethyl nucleoside; and
N^{Z} is a 2'-O-methoxyethyl nucleoside;

d. each R is a 2'-O-methoxyethyl nucleoside; X is 1;
each N^{B} is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is an S-cEt nucleoside;

e. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an LNA nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside; or

f. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an LNA nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is an LNA nucleoside.

18. The compound of claim 1, wherein the modified oligonucleotide has a structure selected from:

$T_E{}^{Me}C_EA_EA_EC_SA_ET_EC_SA_EG_ET_EC_ST_EG_EA_EU_SA_EA_EG_EC_ST_EA_E$, and

$T_E{}^{Me}CAAC_SATC_SAGTC_STGAU_SAAGC_STA_E$

wherein nucleosides not followed by a subscript indicate β-D-deoxyribonucleosides, nucleosides followed by a subscript "E" indicate 2'-MOE nucleosides, nucleosides followed by a subscript "S" indicate S-cEt nucleosides, and superscript "Me" indicates a 5-methyl group on the base of the nucleoside.

19. The compound of claim 2 wherein:

a. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside;

b. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an S-cEt nucleoside;

each N^Q is a 2'-O-methoxyethyl nucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside;

c. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is an S-cEt nucleoside;

d. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an LNA nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside; or

e. N^M is a 2'-O-methoxyethyl nucleoside;

each N^B is an LNA nucleoside;

each N^Q is a β-D-deoxyribonucleoside; and

N^Z is an LNA nucleoside.

20. The compound of claim 2, wherein the modified oligonucleotide has a structure selected from:

$A_EC_SATC_SAGTC_STGAU_SAAGC_STA_E$,

$A_EC_SA_ET_EC_SA_EG_ET_EC_ST_EG_EA_EU_SA_EA_EG_EC_ST_EA_E$,

$A_E^{Me}C_SAT^{Me}C_SAGT^{Me}C_STGAT_SAAG^{Me}C_STA_E$,

$A_EC_SATC_SAGTC_STGAU_SAAGC_STA_S$, and

$A_E^{Me}C_SAT^{Me}C_SAGT^{Me}C_STGAT_SAAG^{Me}C_STA_S$,

wherein nucleosides not followed by a subscript indicate β-D-deoxyribonucleosides, nucleosides followed by a subscript "E" indicate 2'-MOE nucleosides, nucleosides followed by a subscript "S" indicate S-cEt nucleosides, and superscript "Me" indicates a 5-methyl group on the base of the nucleoside.

21. The compound of claim 3 wherein:

a. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside;

N^Y is a β-D-deoxyribonucleoside; and

N^Z is a 2'-O-methoxyethyl nucleoside;

b. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside;

N^Y is a β-D-deoxyribonucleoside; and

N^Z is an S-cEt nucleoside; or

c. each R is a 2'-O-methoxyethyl nucleoside; X is 1;

each N^B is an S-cEt nucleoside;

each N^Q is a β-D-deoxyribonucleoside;

N^Y is an S-cEt nucleoside; and

N^Z is an S-cEt nucleoside.

22. The compound of claim 4 wherein:

a. N^M is a 2'-O-methoxyethyl nucleoside;
each N^B is an S-cEt nucleoside;
each N^Q is a β-D-deoxyribonucleoside;
N^Y is a β-D-deoxyribonucleoside;
N^Z is a 2'-O-methoxyethyl nucleoside; and

b. N^M is a 2'-O-methoxyethyl nucleoside;
each N^B is an S-cEt nucleoside;
each N^Q is a β-D-deoxyribonucleoside;
N^Y is a β-D-deoxyribonucleoside; and
N^Z is an S-cEt nucleoside;

c. N^M is a 2'-O-methoxyethyl nucleoside;
each N^B is an S-cEt nucleoside;
each N^Q is a β-D-deoxyribonucleoside;
N^Y is an S-cEt nucleoside; and
N^Z is an S-cEt nucleoside.

23. The compound of claim 5 wherein:
N^M is a 2'-O-methoxyethyl nucleoside;
each N^B is an S-cEt nucleoside;
each N^Q is a β-D-deoxyribonucleoside; and
N^Z is a 2'-O-methoxyethyl nucleoside.

24. The compound of any of the above claims wherein the modified oligonucleotide has the nucleobase sequence of SEQ ID NO: 3 or wherein the modified oligonucleotide has the nucleobase sequence of SEQ ID NO: 4, and wherein each T in the sequence is independently selected from a T and a U.

25. Use of a compound of any of claims 1 to 24 in the manufacture of a medicament for inhibiting the activity of miR-21 in a cell, wherein the medicament is to be contacted to a cell.

26. The use of claim 25, wherein the cell is *in vivo* or wherein the cell is *in vitro*.

27. The use of claim 25 or 26 wherein the cell is a fibroblast cell, a hyperproliferative cell, a keratinocyte, or a hypoxic cell.

28. Use of a compound of any of claims 1 to 24 in the manufacture of a medicament for decreasing collagen expression in a cell, wherein the medicament is to be contacted to a cell.

29. Use of a compound of any of claims 1 to 24 in the manufacture of a medicament for treating, preventing or delaying the onset of a disease associated with miR-21 in a subject having a disease associated with miR-21, wherein the medicament is to be administered into the subject having a disease associated with miR-21.
30. The use of claim 29, wherein the disease is fibrosis.
31. The use of claim 30, wherein the fibrosis is selected from kidney fibrosis, lung fibrosis, liver fibrosis, cardiac fibrosis, skin fibrosis, age-related fibrosis, spleen fibrosis, scleroderma, and post-transplant fibrosis.
32. The use of claim 31 wherein:
    a. the kidney fibrosis is present in a subject having a disease selected from glomerulosclerosis, tubulointerstitial fibrosis, IgA nephropathy, interstitial fibrosis/tubular atrophy; chronic kidney damage, glomerular disease, glomerulonephritis, diabetes mellitus, idiopathy focal segmental glomerulosclerosis, membranous nephropathy, collapsing glomerulopathy, chronic recurrent kidney infection, and end stage renal disease;
    b. the kidney fibrosis results from acute or repetitive trauma to the kidney;
    c. the liver fibrosis is present in a subject having a disease selected from chronic liver injury, hepatitis infection, non-alcoholic steatohepatitis, and cirrhosis; the pulmonary fibrosis is idiopathic pulmonary fibrosis; and/or
    d. the subject has chronic obstructive pulmonary disease.
33. Use of a compound of any of claims 1 to 24 in the manufacture of a medicament for treating a fibroproliferative disorder in a subject, wherein the medicament is to be administered into the subject.
34. The use of any of claims 25 to 33 comprising selecting a subject having elevated miR-21 expression in one or more tissues.
35. The use of any of claims 29 to 33 wherein the subject is in need of improved organ function, wherein the organ function is selected from cardiac function, pulmonary function, liver function, and kidney function.
36. The use of any of claims 29 to 35 wherein the adminstration improves organ function in the subject, wherein the organ function is selected from cardiac function, pulmonary function, liver function, and kidney function.
37. The use of any of claims 29 to 36 wherein said treatment comprising administration of at least one therapeutic agent selected from an anti-inflammatory agent, an immunosuppressive agent, an anti-diabetic agent, digoxin, a vasodilator, an angiotensin II

converting enzyme (ACE) inhibitors, an angiotensin II receptor blockers (ARB), a calcium channel blocker, an isosorbide dinitrate, a hydralazine, a nitrate, a hydralazine, a beta-blocker, a natriuretic peptides, a heparinoid, and a connective tissue growth factor inhibitor.

38. The use of claim 29, wherein the disease is cancer.
39. The use of claim 38 wherein the cancer is liver cancer, breast cancer, bladder cancer, prostate cancer, colon cancer, lung cancer, brain cancer, hematological cancer, pancreatic cancer, head and neck cancer, cancer of the tongue, stomach cancer, skin cancer, or thyroid cancer.
40. The use of any of claims 38 or 39 wherein said treatment further comprising administration of at least one additional anti-cancer therapy to the subject.
41. The use of any of claims 25 to 40, wherein the subject is a human.
42. The use of any of claims 25 to 41, wherein the compound is present as a pharmaceutical composition.
43. A compound of any of claims 1 to 24, for use in therapy.
44. A compound of any of claims 1 to 24, for use in the treatment of fibrosis.
45. A compound of any of claims 1 to 24, for use in promoting wound healing.
46. A compound of any of claims 1 to 24, for use in treating cancer.
47. A compound of any of claims 1 to 24, for use in preventing and/or delaying the onset of metastasis.
48. A compound of any of claims 1 to 24, for use in treating cardiac disease.
49. Use of a compound of any one of claims 1 to 24 for the preparation of a medicament.
50. Use of a compound of any one of claims 1 to 24 for the preparation of a medicament for treating fibrosis.
51. Use of a compound of any one of claims 1 to 24 for the preparation of a medicament for promoting wound healing.
52. Use of a compound of any one of claims 1 to 24 for the preparation of a medicament for treating cancer.
53. Use of a compound of any one of claims 1 to 24 for the preparation of a medicament for preventing and/or delaying the onset of metastasis.